MedPage Today on MSN
No survival benefit in advanced breast cancer with frontline CDK4/6 inhibition
Median overall survival of 4 years with upfront CDK4/6 inhibition or in second line ...
Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...
Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial Earlier detection of cancer offers an opportunity to ...
The middle meningeal artery (MMA) has emerged as a potential therapeutic target for severe, treatment-resistant headache syndromes. Growing evidence suggests that the MMA and its dural branches are ...
Although progression-free survival was similar across racial groups, overall survival was shorter for Black patients with ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
Targeted indoor residual spraying focuses insecticide applications on common resting surfaces of Aedes aegypti mosquitoes (an arboviral disease vector) in houses, such as exposed lower sections of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results